Lung cancer has become a leading cause of death among people living with human immunodeficiency virus (HIV) (PLWH). Over 40% of PLWH in the United States smoke cigarettes; HIV independently increases the risk of lung cancer.
A ntiretroviral therapy (ART) has dramatically improved the life expectancy of people living with human immunodeficiency virus (HIV) (PLWH), with a concomitant shift in morbidity and mortality from AIDS to non-AIDS diseases. 1, 2 Much of the non-AIDS disease burden is tobacco-related. Over 40% of PLWH in the United States smoke cigarettes, more than double the smoking prevalence in the general population. [3] [4] [5] [6] [7] Among PLWH undergoing ART, smoking now reduces life expectancy more than HIV itself. [8] [9] [10] Tobacco use and HIV together may accelerate the development of lung cancer. [11] [12] [13] [14] The risk of lung cancer is increased by the presence of HIV through mechanisms likely involving chronic inflammation, immunomodulation, and other infections. 11, [15] [16] [17] [18] [19] Lung cancer is the leading cause of cancer death among PLWH undergoing ART and is among the leading causes of death overall in this population. 13, 20 Despite the high smoking prevalence and the risk of lung cancer and other tobacco-related diseases, smoking cessation programs generally have not been successfully implemented in HIV care. As the population of PLWH in the United States ages, estimates of projected comorbidities can help guide where to direct attention and resources in HIV care. We sought to understand the likely impact of smoking cessation on lung cancer mortality among PLWH in HIV care in the United States. We compared the risk of lung cancer death against the risks of death from other causes as a function of smoking exposure.
Methods

Analytic Overview
We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-US model, a validated, widely published Monte Carlo microsimulation of HIV disease and treatment. 10, [21] [22] [23] After populating the model with published data, we projected lung cancer mortality among PLWH in HIV care according to smoking exposure. We defined smoking exposure by both smoking status (current, former, or never) and, for current and former smokers, intensity (heavy, moderate, or light) based on number of cigarettes per day. We accounted for competing risks of death from AIDS-related and non-AIDSrelated causes, the latter stratified by smoking exposure. We modeled cohorts of 1 million men or women of a particular smoking exposure entering HIV care at a specific age (eg, 30, 40, or 50 years) . The primary outcome was cumulative lung cancer mortality by age 80 years. We combined the model-generated estimates with published epidemiologic data to project the total expected lung cancer deaths among PLWH in care in the United States.
Model Overview
For this analysis, an individual enters the model at the time of linkage to HIV care and is followed until death or age 80 years, whichever comes first. The model draws randomly from user-defined initial distributions of CD4 count and HIV RNA and tracks clinical outcomes as an individual transitions monthly through states of disease progression and treatment. Probabilities of transition between HIV-related health states depend on factors including current CD4 count and HIV RNA. All individuals are ART eligible, regardless of CD4 count. 24 An individual may die from an AIDS-related cause (opportunistic infection or chronic AIDS-related disease), lung cancer, or another non-AIDS-related cause (eg, cardiovascular disease; eFigure 1 in the Supplement). Model details are available at http://www.massgeneral.org/mpec /cepac/.
Cohort Stratifications
We simulated cohorts stratified by sex, age at entry to HIV care, and smoking exposure (eg, current moderate smokers, former heavy smokers). We assumed no change in smoking status or intensity stratification over time. Former smokers are stratified by past smoking intensity. Within each cohort of former smokers, all individuals stop smoking at the same age (at entry to HIV care, except in sensitivity analysis, in which they quit later) and remain abstinent. We did not evaluate those who had quit smoking before entering HIV care.
likely to survive long enough to develop lung cancer. Recognizing that smoking emerges as an important competing risk in the presence of virologic suppression, we assumed, in the base case, complete ART adherence and no loss to follow-up from HIV care. These in-care individuals are more likely to participate in a smoking cessation intervention. In sensitivity analysis, we relaxed this assumption, accounting for reported rates of ART nonadherence and loss to follow-up (Supplement). 27 Additional specifications are described elsewhere.
23,27
Model Validation
There are few published data on smoking-related mortality specific to PLWH. We therefore pursued 2 validation strategies. First, we compared our model-generated cumulative lung cancer mortality among HIV-uninfected people to results reported in general population studies in Western Europe.
28,29
Second, we compared our model-generated cumulative lung cancer mortality among PLWH (accounting for ART nonadherence and loss to follow-up) with the modeled cumulative lung cancer incidence reported by the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) (Supplement).
30,31
Input Parameters
Cohort Characteristics
We simulated PLWH reflecting those initiating HIV care in the United States 25, [32] [33] [34] [35] [36] [37] [38] [39] (Table 1 and Supplement). In the base case, we assumed the same CD4 distribution regardless of cohort age at entry to care.
Cohort Stratifications by Smoking Exposure
Smoking intensity for current and former smokers was based on number of cigarettes per day as derived by Rosenberg et al, 25 who categorized US smokers into quintiles of cigarettes per day stratified by sex, age, and 5-year birth cohort, through the year 2000. 25 Among current and former smokers, we considered the fifth, third, and first quintiles to be heavy, moderate, and light smokers. For example, among 40-year-old men, heavy, moderate, and light smokers consumed 35, 18, and 2 cigarettes per day, respectively (Table 1) . These quantities changed with age according to published data (Supplement).
25
Lung Cancer Mortality To derive monthly lung cancer mortality by smoking exposure, we combined US general population data on lung cancer mortality rates in 2000 (to match the latest year of the lung cancer-deleted life tables 25 ), lung cancer mortality risk ratios for current and former smokers (further stratified by smoking intensity) vs never smokers, and the proportions of current, former, and never smokers in the population (Supplement). 25, 36, [40] [41] [42] Compared with never smokers, the lung cancer mortality risk ratio for male and female current moderate smokers was 23.6 and 24.2, respectively, and for those who quit at age 40 years, it was 4.3 and 4.5. The derived smoking exposure-stratified lung cancer rates were not specific to PLWH. Therefore, in the base case, we accounted for an HIV-associated independent risk of lung cancer by multiplying the derived rates by 1.7. This was the multivariable-adjusted risk ratio (PLWH vs HIV-uninfected people) reported by the Veterans Aging Cohort Study, 11 the largest study of the association between HIV and lung cancer.
Lung Cancer-Deleted, Non-AIDS-Related Mortality We applied lung cancer-deleted, non-AIDS-related mortality probabilities (eg, from other cancers and cardiovascular disease) based on published lung cancer-deleted life tables through 2000 (Supplement).
25 Mortality risks were stratified by sex, age, and smoking exposure. In the base case, we assumed no HIV-associated increase in these causes of death. We did not specify the cause of death within this group; estimates would have been inaccurate owing to the absence of many cause-deleted life tables.
Sensitivity Analysis
To understand the robustness of our findings under parameter uncertainty, we performed sensitivity analyses with alternative assumptions and parameter estimates. These included (1) accounting for reported rates of ART nonadherence and loss to follow-up from HIV care, which increase AIDS-related death risk; (2) varying the HIV-associated risk ratio for lung cancer from 1.0 to 1.9 11 ; (3) varying initial CD4 count at entry to HIV care, which affects AIDS-related death risk; and (4) varying when former smokers quit: 10 or 20 years after entering HIV care, rather than at the time of entering care.
Our base case did not include a link between HIV and other non-AIDS-related causes of death (besides lung cancer). This reflected the inconsistency of reported smoking-adjusted, HIVassociated risks of death from these causes. However, we conducted an additional sensitivity analysis using a multiplicative risk factor of 1.7 to increase the independent effect of HIV on other non-AIDS-related mortality, including that from other cancers and cardiovascular disease. This value highlighted the reported HIV-conferred risk of myocardial infarction and matched the HIV-associated lung cancer risk ratio we applied in the base case. [37] [38] [39] 43 Population-Level Impact
We derived the number of current, former, and never smokers among PLWH aged 20 to 64 years in HIV care in the United States by sex and 5-year age increment (the overall prevalence of current, former, and never smokers among PLWH was approximately 42%, 20%, and 37%, respectively, in 2009).
3,31 Accounting for reported rates of ART nonadherence and loss to follow-up from care, we used modelgenerated cumulative lung cancer mortality for each sex, age, and smoking stratum to derive the expected total number of lung cancer deaths by age 80 years among PLWH in HIV care in the United States. To examine the potential impact of a smoking cessation intervention, we estimated the reduction in lung cancer deaths if 20% of current smokers in each sex and age cohort were to quit smoking (Supplement).
Results
Model Validation
For HIV-uninfected people, model-generated cumulative lung cancer mortalities by age 75 years for current heavy smokers were 24.5% and 19.5% for men and women, respectively; these values are similar to those reported in the United Kingdom, 24.4% and 18.5% (eTables 1 and 2 in the Supplement). 28 For 20-year-old PLWH in the United States, our model-generated cumulative lung cancer mortality by age 75 years was 5.0%, while the modeled cumulative lung cancer incidence reported by NA-ACCORD was 3.7% (Supplement).
30
Base Case
Among men, cumulative lung cancer mortality by age 80 years for heavy, moderate, and light current smokers entering HIV care at age 40 years was 28.9%, 23.0%, and 18.8%, respectively; for heavy, moderate, and light former smokers who quit smoking at age 40 years, it was 7.9%, 6.1%, and 4.3%; and for never smokers, it was 1.6%. Among women, the corresponding respective cumulative lung cancer mortality for heavy, Figure 1 ). Cumulative lung cancer mortality for ART-adherent current and never smokers varied little by age at entry to HIV care, with slightly higher results among those entering care at older ages owing to survival bias ( Table 2) .
Risk of Mortality From Lung Cancer vs Other Causes
Risks of mortality from lung cancer vs other causes varied by smoking exposure. For men who entered HIV care at age 40 years, adhered to the ART regimen, and continued to smoke at a moderate ("average") level, cumulative mortality from lung cancer was 10 times that from AIDS-related causes (23.0% vs 2.3%; Figure 2A ). The mortality for former smokers in this category is illustrated in Figure 2B , and for never smokers, it is illustrated in eFigure 2A in the Supplement. For women who entered HIV care at age 40 years, adhered to the ART regimen, and continued to smoke at a moderate ("average") level, cumulative mortality from lung cancer was 8 times that from AIDS-related causes (20.9% vs 2.5%). Depending on sex and smoking intensity, ART-adherent smokers were 6 to 13 times more likely to die from lung cancer than from AIDS-related causes. For 40-year-old ARTadherent men who were current moderate smokers, the combined cumulative mortality from lung cancer and other non-AIDS-related causes-both of which were increased by smoking-was approximately 35 times that from AIDSrelated causes (79.9% vs 2.3%); for women in this category, it was approximately 27 times higher (66.6% vs 2.5%) (eTable 3 in the Supplement). See eTable 4 in the Supplement for results for different ages at entry to HIV care.
Sensitivity Analysis
For the sensitivity analyses described in the Methods section, we report instances where input data were most uncertain and/or where variation in the underlying parameter had a material impact on our findings. Results of other sensitivity analyses (including varying CD4 count at entry to HIV care and timing of smoking cessation) are reported in the Supplement.
Incomplete Adherence and Loss to Follow-up When we accounted for reported rates of ART nonadherence and loss to follow-up from HIV care, cumulative lung cancer mortality among moderate smokers decreased, and cumulative AIDS-related mortality increased ( Figure 2C and D). The results for never smokers are depicted in eFigure 2B in the Supplement. For men who were current heavy smokers, cu- mulative lung cancer mortality (22.7%) was similar to AIDSrelated mortality (23.0%); for women, the corresponding results were 21.6% vs 25.5% (eTable 5 in the Supplement).
Varying HIV-Associated Risks of Lung Cancer and of Other Non-AIDS-Related Mortality
Model-generated cumulative mortality varied depending on the HIV-associated risk ratios applied for lung cancer and for other non-AIDS-related causes. For male and female current moderate smokers, cumulative lung cancer mortality varied from 10.5% to 23.0%, and cumulative other non-AIDSrelated mortality varied from 45.7% to 78.0%. The lower numbers reflected scenarios assuming no direct influence of HIV on these causes of death (Table 3) .
Population-Level Impact
Applying sex-and age-specific, model-projected results to the approximately 644 200 PLWH aged 20 to 64 years in care in the United States (including current, former, and never smokers), 59 900 lung cancer deaths by age 80 years are expected (9.3% of this population) if smoking status does not change. If 20% of the 273 200 current smokers quit, their lung cancer risk would decrease to that of former smokers, and 6900 (11.5%) lung cancer deaths could be averted.
Discussion
Using a microsimulation model, we found that ARTadherent PLWH in the United States who smoke cigarettes are 6 to 13 times more likely to die from lung cancer than from AIDS-related causes. Even when accounting for reported rates of ART nonadherence and loss to follow-up, we found that nearly 10% of PLWH initially linked to HIV care (including both smokers and nonsmokers) are expected to die from lung cancer if smoking habits do not change. Smoking cessation could substantially reduce lung cancer risk for an individual and avert many lung cancer deaths at the population level. People with HIV whose virus is suppressed now have a life expectancy approaching that of HIV-uninfected people.
44 However, life expectancy gaps persist, and smoking is a key driver of this difference. 45 This smoking footprint will likely grow as PLWH age and develop lung cancer and other smokingassociated diseases. Lung cancer was already the leading cause of death in a study of PLWH in France in 2010; the smoking ART indicates antiretroviral therapy; LTFU, loss to follow-up. The intensity of smoking (number of cigarettes per day) was considered to be moderate ("average"). Current smokers continued smoking until the end of follow-up. Former smokers quit at age 40 years and remained abstinent. "Number at risk" tables are not needed here. The graphs represent model-generated outcomes, each line a simulated cohort of 1 million people entering HIV care at age 40 years. While some people are lost to follow-up from clinical care (in the sensitivity analyses that allow for loss to follow-up), the model still keeps track of them, recording when and how they die, so they are not lost from the model or from the results. The number at risk are the number of people still alive at each time point, with no other form of censoring. a The model-generated results are for people who entered HIV care at age 40 years and were followed up until death or age 80 years. These simulations assumed moderate ("average") intensity of smoking, based on number of cigarettes per day. Individuals continued smoking until the end of follow-up. The HIV-associated mortality risk ratios represent the independent risk conferred by HIV, compared with HIV-uninfected people, of mortality from either lung cancer or other non-AIDS-related causes. A mortality risk ratio of prevalence among PLWH is similar in France and the United States. 3, 20, 46 In stratifying mortality risks by smoking status and intensity, our results can inform important conversations between clinicians and PLWH who smoke, helping both clinician and patient understand the patient's risks of different diseases and the potential benefits of smoking cessation. Recognizing the increased risk of death from lung cancer vs that from traditionally feared AIDS-related causes may motivate a smoker to quit smoking, 47 although this is not always the case. Our analyses also accounted for the smoking-conferred increase in risk of death from causes besides lung cancer and AIDS-this includes other cancers, other lung diseases, and cardiovascular disease. Our results provide evidence for HIV care programs and policymakers to include smoking cessation interventions as a key component of the comprehensive care of PLWH. Though smoking cessation is challenging, smoking prevalence among the US general population has decreased substantially in recent decades, from 42% in 1965 to 15% in 2015. 7,48 While the current smoking prevalence among PLWH is much higher than that among HIV-uninfected people, a similar proportion of smokers in the 2 groups want to quit, offering hope for a potential decrease in smoking prevalence in PLWH as well.
49
Perhaps counterintuitively, lung cancer risk is linked to adherence to HIV therapy. Those who are not ART-adherent are more likely to die of AIDS-related causes before developing lung cancer. Nonetheless, even when accounting for reported rates of ART nonadherence and loss to follow-up from HIV care, we found that for male heavy smokers, the risk of dying from lung cancer is similar to the risk of dying from AIDS-related causes.
Limitations
Our results are subject to limitations inherent in the assumptions and simplifications of any model-based study. These include the following: (1) using data from the US general population in 2000 in the absence of smoking-stratified lung cancer data for PLWH; (2) uncertainty around the HIVconferred risk of lung cancer, which could be lower or higher than what we applied in this analysis, and could vary by age 11, [13] [14] [15] [16] [17] 50 ; (3) assuming no relationship between CD4 count and lung cancer risk, given conflicting reports affected by confounders such as smoking intensity 15, 19, [51] [52] [53] [54] ; (4) assuming that the HIV-associated increase in lung cancer mortality is similar to the increase in incidence, since median survival after lung cancer diagnosis is short 11, 40 ; (5) Though the model-generated estimates may be influenced by input parameter uncertainty, the magnitude of smokingrelated harm with respect to lung cancer and other non-AIDS-related mortality, and the magnitude of the benefit from smoking cessation, remain robust, as shown in our sensitivity analysis.
Conclusions
In conclusion, there is a large expected burden of lung cancer among PLWH in the United States because (1) the smoking prevalence is very high in this population; (2) 
METHODS: ADDITIONAL INFORMATION
Model Overview
In the model, all individuals are eligible for immediate antiretroviral therapy (ART) with dolutegravir/abacavir/lamivudine, a regimen recommended for initial treatment of HIV. The efficacy of ART (the initially suppressed are subject to a regimen-specific monthly probability of treatment failure after 48 weeks, which 48 is inversely correlated with adherence. Treatment failure is detected through quarterly HIV RNA monitoring. Those 49 who fail treatment are eligible to receive a subsequent ART regimen. Individuals can be switched to an alternative 50 ART regimen if drug toxicity is noted. We assumed complete adherence to ART in the base case but accounted for 51 incomplete adherence in sensitivity analysis.
53
Loss to Follow-up
54
In the base case, we assumed that all individuals are retained in HIV care (i.e., none are lost to follow-up). In sensitivity analysis, we accounted for loss to follow-up from HIV care, wherein individuals discontinue ART. The 56 probability of loss to follow-up is inversely correlated with adherence. Following loss to follow-up, individuals have 57 a monthly probability of returning to care.
59
AIDS-Related Causes of Death
60
In the model, AIDS-related causes of death are those from opportunistic infections or chronic AIDS-related disease.
61
Opportunistic infections include Pneumocystis jiroveci pneumonia, Mycobacterium avium complex infection, 62 toxoplasmosis, cytomegalovirus infection, severe fungal infection, and severe bacterial infection. Chronic AIDS-63 related mortality is that related to classic HIV syndromes and disorders, such as chronic wasting, that are not directly 64 caused by an opportunistic infection. Input parameters for incidence and mortality from these diseases are derived from the literature and are described elsewhere (http://www.massgeneral.org/mpec/cepac/).
67
Model Validation
68
Our first validation strategy was done against case-control studies in Western European general populations. These reported cumulative lung cancer mortality by age 75, stratified by smoking exposure, without competing causes of 70 death.
1,2 We used our model to predict cumulative lung cancer mortality by age 75, stratified by sex and smoking 
77
ACCORD results were not stratified by sex or by smoking exposure (smoking prevalence was not reported). We 78 used our model to predict cumulative lung cancer mortality among 20 year-old PLWH in care in the US, initially 79 stratified by sex and smoking status. Because we did not have smoking intensity (cigarettes per day) data specific to 80 20 year-old PLWH, we assumed that all smokers consumed a moderate ("average") number of cigarettes per day.
We accounted for reported rates of non-adherence to ART and loss to follow-up from HIV care, as described in a -and the prevalence of current, former, and 86 never smokers among 20 year-old PLWH in care in the US -37.6%, 7.3%, and 55.1%, according to the CDC. 5 We 87 assumed equal smoking prevalence among men and women with HIV. 5 We assumed no change in smoking status 88 over time. 
109
Lung Cancer Mortality
110
In the model, we applied a monthly probability of dying from lung cancer based on sex, age, and smoking exposure.
111
First, we derived annual lung cancer mortality rates in the US general population according to sex, five-year age group, and smoking exposure. The data we used in these derivations were: 1) overall lung cancer mortality rates we multiplied the derived rates by 1.7 to account for an independent risk of lung cancer conferred by HIV. 11 We 120 converted the annual rates to monthly probabilities for use in our model, using the equation:
122
MonthlyProbability = 1 -exp(-AnnualRate/12)
124
Lung Cancer-Deleted, Non-AIDS-Related Mortality since smoking cessation, M Former = mortality rate for former smokers, M Never = mortality rate for never smokers, and our model.
Sensitivity Analysis
Incomplete Adherence to Antiretroviral Therapy and Loss to Follow-Up from HIV Care
In a sensitivity analysis, we accounted for reported rates of non-adherence to ART and loss to follow-up from HIV care. The distribution of ART adherence levels in the modeled cohorts reflects studies of medication possession ratios (MPRs) among PLWH in the US. 14, 15 Based on these studies, we applied MPR distributions as follows: 3% of people had MPR <50%, 51% had MPR between 50% and 95%, and 46% had MPR >95%; these values translated to 157 mean MPR 89% and standard deviation 14%. 16 We fit a logit-normal distribution to these data. 16 The model 158 randomly draws a value from this distribution to generate an adherence level for an individual. As described elsewhere, 16 we used published data to derive the relationship between adherence and virologic suppression.
17
160
Overall, the suppression rate for the entire population matched clinical trial data, with no suppression if an 161 individual's MPR was <5%, and virtually certain suppression if an individual's MPR was >91%.
163
We derived adherence-specific rates of loss to follow-up to match retention-in-care data from the HIV Research
164
Network. 16, 18 Loss to follow-up rates ranged from 0.1 to 84.5/100 person-years, depending on adherence. We 165 assumed that PLWH in the US returned to care at approximately half the rate of those in the Danish HIV Cohort
166
Study. 19 Beginning six months after loss to follow-up, individuals had a 1.5% monthly probability of returning to 167 care which increased to 50% in the month of an acute opportunistic infection.
16
168 169
Varying the HIV-Associated Risk Ratio for Lung Cancer
170
In the base case, we applied an HIV-associated independent risk of lung cancer (versus HIV-uninfected persons) of 171 1.7, based on the result reported in the largest study to examine the relationship between HIV and lung cancer. 11 In a 172 sensitivity analysis, we varied the HIV-associated risk, examining risk ratios of 1.5 and 1.9 (the lower and upper
173
bounds of the 95% confidence interval reported in the aforementioned study), as well as a risk ratio of 1.0 (i.e., no independent risk of lung cancer conferred by HIV).
176
Varying the Initial CD4 Cell Count at Entry to HIV Care
In the base case, we applied an initial distribution of CD4 count based on NA-ACCORD data, where mean (standard deviation) CD4 count at entry to care was 360/ L (280/ L). 20 In a sensitivity analysis, we changed the initial CD4
count to either 200/ L for all or 500/ L for all (standard deviation of zero). Regardless of initial CD4 count, all 180 subjects were eligible to immediately initiate ART, and we assumed complete adherence to ART.
182
Varying When Former Smokers Quit
In the base case, we assumed that former smokers quit smoking upon entering HIV care. In a sensitivity analysis, we 184 assumed instead that they quit 10 or 20 years after entering HIV care. In these scenarios, they had the same mortality 185 risks as current smokers until they quit, at which point their mortality risks decreased to those of former smokers.
187
Population-Level Impact
188
We estimated the total number of expected lung cancer deaths by age 80 among PLWH aged 20-64 in care in the 189 US, and the number of lung cancer deaths that could be averted if a proportion of current smokers were to quit smoking. We have previously described the methodology of determining the number of current, former, and never
191
smokers by sex and age group. 21 In brief, first, we obtained data on the number of new and established diagnoses of
192
HIV infection in the US, stratified by five-year age increment. 4 Next, we multiplied these numbers by the linkage to 193 care rate (77.5%) among those diagnosed with HIV. 22 We then multiplied the number of people linked to care within each five-year age group by the age-specific prevalence of current, former, and never smokers among PLWH, as
195
reported by the CDC, 5 to obtain the number of current, former, and never smokers in each five-year age group. We 196 used the published sex breakdown from the CDC (approximately 75% men and 25% women) 4 and assumed equal 197 smoking prevalence among men and women with HIV. The smoking prevalence data we used for this HIV 198 population-level analysis had been stratified by smoking status but not by intensity, so we assumed that all smokers 199 were moderate ("average") smokers, reflecting the middle quintile of daily cigarette consumption. 5,6 Finally, we 200 multiplied these counts by our model-generated results regarding the cumulative lung cancer mortality by age 80, depending on sex, age, and smoking status , to derive the total expected number of lung cancer deaths if smoking status did not change. We then converted a proportion (20%) of current smokers in each five-year age group to former smokers, to derive the number of lung cancer deaths that could be prevented if this proportion were to stop smoking now.
206
RESULTS: ADDITIONAL INFORMATION
208
Model Validation
Our model-generated cumulative lung cancer mortalities for HIV-uninfected people were similar to those reported in preferentially chose those published data that included 95% confidence intervals.
smokers were 12.5%, 1.5%, and 0.7%. The corresponding model-generated cumulative lung cancer mortalities for and women and of current, former, and never smokers among 20 year-old PLWH in care in the US, we derived a 217 cumulative lung cancer mortality of 5.0% by age 75. In an NA-ACCORD study, the reported modeled cumulative Our projected cumulative lung cancer mortality was slightly higher than that reported in the NA-ACCORD study.
221
The prevalence of current and former smokers was not reported in that study, but another NA-ACCORD study 222 reported lower smoking prevalence compared with the CDC data we used, which may explain the difference in 
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Varying the Initial CD4 Count at Entry to Care
241
There was little difference in the cumulative mortality from lung cancer, other non-AIDS-related causes, and AIDS-242 related causes when varying the initial CD4 count (eTable 7). These analyses assumed immediate ART initiation,
243
complete adherence to ART, and no loss to follow-up from HIV care.
245
Varying 
